US Edition
Diagnosed prevalent cases of HER2- breast cancer across 8MM set to reach 4.12 mn in 2034 - Express Pharma
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Diagnosed prevalent cases of HER2- breast cancer across 8MM set to reach 4.12 mn in 2034 - Express Pharma
The burden of five-year diagnosed prevalent cases of HER2-Negative (HER2-) breast cancer is expected to increase at an annual growth rate (AGR) of 1.42 per cent from around 3.61 million in 2024 to 4.12 million in 2034 across the eight major markets (8MM*), forecasts GlobalData. GlobalData’s latest report, “HER2-Negative Breast Cancer: Epidemiology Forecast to 2034,” reveals that the increase is partly attributed to an increased incidence of HER2…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
